mbg-logo-500px

Maxwell Biotech Group currently has 9 biotech companies in its portfolio, which are engaged in the development of 11 innovative clinical stage drugs. 

mbg-portfolio-sidebar-hepaterambg-portfolio-sidebar-neuromaxmbg-portfolio-sidebar-infectexmbg-portfolio-sidebar-eleventambg-portfolio-sidebar-osterosmbg-portfolio-sidebar-photonicsmbg-portfolio-sidebar-oncomaxmbg-portfolio-sidebar-metamaxmbg-portfolio-sidebar-cardionova

Biotechnology company

News

Home > News

Eleventa Announce Completion of Patient Enrollment in Phase 3 Clinical Trial of CRTH2 antagonist Timapiprant for the treatment of allergic asthma

29.09.2016 by in category News

Eleventa Announce Completion of Patient Enrollment in Phase 3 Clinical Trial of CRTH2 antagonist Timapiprant for the treatment of allergic asthma Eleventa Ltd. (Moscow, Russia), a portfolio company of Maxwell Biotech Venture Fund (MBVF), and its development partner, Oxagen Limited (Abingdon, UK), today announced the completion of patient enrollment in the a Phase 3 clinical […]

0 0 Read more

Eleventa has enrolled first patients in Phase III multicenter clinical trial

01.08.2014 by in category News

Eleventa has enrolled first patients in Phase III multicenter clinical trial Russian biotech company Eleventa is enrolling its first patients at 20 Russian clinical centers in its Phase III clinical trial for the anti-inflammatory drug OC000459.  The drug is aimed at the treatment of mild to moderate bronchial asthma.  Eleventa is supported by investments from […]

0 0 Read more

Eleventa has become a Skolkovo resident

20.11.2012 by in category News

Eleventa has become a Skolkovo resident Eleventa, Ltd formed in September 2012 for the development and commercialization of innovative products for the treatment of asthma and other allergic respiratory diseases has recently become resident of Biomed Cluster at Skolkovo Innovation Center. Eleventa became the eighth “Maxwell Biotech Group” portfolio company listed as resident of Skolkovo. […]

0 0 Read more

 

© Eleventa, 2012—2020